Retireful LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retireful LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 714 shares of the biopharmaceutical company's stock, valued at approximately $751,000.

Other hedge funds have also added to or reduced their stakes in the company. Quent Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company's stock worth $375,000 after buying an additional 19 shares during the period. Bessemer Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 107.1% in the 1st quarter. Bessemer Group Inc. now owns 5,075 shares of the biopharmaceutical company's stock valued at $4,886,000 after buying an additional 2,624 shares during the period. Lake Street Advisors Group LLC increased its position in Regeneron Pharmaceuticals by 41.3% in the 1st quarter. Lake Street Advisors Group LLC now owns 746 shares of the biopharmaceutical company's stock valued at $718,000 after buying an additional 218 shares in the last quarter. Pitcairn Co. raised its stake in Regeneron Pharmaceuticals by 6.5% during the 1st quarter. Pitcairn Co. now owns 838 shares of the biopharmaceutical company's stock worth $807,000 after buying an additional 51 shares during the period. Finally, Ossiam grew its stake in Regeneron Pharmaceuticals by 5.9% in the first quarter. Ossiam now owns 5,429 shares of the biopharmaceutical company's stock valued at $5,225,000 after acquiring an additional 302 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $1.25 during trading hours on Wednesday, reaching $743.35. 654,394 shares of the company traded hands, compared to its average volume of 535,216. The stock has a market capitalization of $81.69 billion, a P/E ratio of 18.43, a P/E/G ratio of 2.86 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average price of $969.72 and a 200-day moving average price of $1,032.16. Regeneron Pharmaceuticals, Inc. has a 12-month low of $736.01 and a 12-month high of $1,211.20.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.